Will the dark sky over advanced renal cell carcinoma soon become brighter?

被引：10

作者：

D'Hondt, V ^{[1
]}

Gil, T ^{[1
]}

Lalami, Y ^{[1
]}

Piccart, M ^{[1
]}

Awada, A ^{[1
]}

机构：

[1] Inst Jules Bordet, Clin Med Oncol, B-1000 Brussels, Belgium

来源：

EUROPEAN JOURNAL OF CANCER | 2005年 / 41卷 / 09期

关键词：

renal cell carcinoma; molecular-targeted therapy; anti-angiogenesis agents; review; new drugs;

D O I：

10.1016/j.ejca.2004.11.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Until recently, immunotherapy has been the most efficient treatment for advanced renal cell carcinoma, but clinical results are largely unsatisfactory. More promising agents are being developed as a result of an improved understanding of the biology of the disease. Several agents that target known biological abnormalities of the disease are now being tested in the clinic. This review describes the encouraging clinical results obtained to date with these new drugs or combinations of drugs. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：1246 / 1253

页数：8

共 48 条

[1]

AMATO RJ, 2003, CRIT REV ONCOL HEMAT, V46, P59

[2]

AMATO RJ, 2002, P AM SOC CLIN ONCOL, V21

[3] Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma [J].

Asakuma, J ;

Sumitomo, M ;

Asano, T ;

Hayakawa, M .

JOURNAL OF UROLOGY, 2004, 171 (02) :897-902

[4] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[5] Neovastat (Æ-941) in refractory renal cell carcinoma patients:: report of a phase II trial with two dose levels [J].

Batist, G ;

Patenaude, F ;

Champagne, P ;

Croteau, D ;

Levinton, C ;

Hariton, C ;

Escudier, B ;

Dupont, E .

ANNALS OF ONCOLOGY, 2002, 13 (08) :1259-1263

[6]

Borgström P, 1998, PROSTATE, V35, P1

[7]

Bukowski RM, 2003, EXPERT OPIN INV DRUG, V12, P1403

[8] Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].

Childs, R ;

Chernoff, A ;

Contentin, N ;

Bahceci, E ;

Schrump, D ;

Leitman, S ;

Read, EJ ;

Tisdale, J ;

Dunbar, C ;

Linehan, WM ;

Young, NS ;

Barrett, AJ ;

Clave, E ;

Epperson, D ;

Mayo, V .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758

[9] A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma [J].

Daliani, DD ;

Papandreou, CN ;

Thall, PF ;

Wang, XM ;

Perez, C ;

Oliva, R ;

Pagliaro, L ;

Amato, R .

CANCER, 2002, 95 (04) :758-765

[10] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

← 1 2 3 4 5 →